2 Beaten-Down Stocks to Avoid Right Now
Just because a stock has been battered doesn't make it an automatic buy. That's only the case if it can bounce back, and in some cases, there are few good reasons to believe it can.
Take Teladoc Health (NYSE: TDOC) and Sarepta Therapeutics (NASDAQ: SRPT). These two healthcare companies have lagged the market this year, but even at their current levels, they don't look particularly attractive. Here's why investors should stay away from them.
Teladoc, a telemedicine specialist, is facing multiple headwinds. First, the company's top line isn't growing nearly as fast as it once was -- that is, if it is moving in the right direction at all. In the second quarter, revenue declined by 2% year over year to $631.9 million.
Source Fool.com
Sarepta Therapeutics Aktie
15,12 €
-7,10 %
Die Community ist unsicher über Sarepta Therapeutics: Zu wenige Buy- und Sell-Einschätzungen vorhanden.
Mit einem Kursziel von 135 € für Sarepta Therapeutics zeigt sich ein beachtliches Wachstumspotenzial gegenüber dem aktuellen Kurs von 15.12 €.
